 
Introduction
One widely investigated strategy of suicide gene therapy or enzyme/prodrug therapy involves transfer of the cDNA for the herpes simplex virus thymidine kinase (HSVtk) gene into tumor cells which then sensitizes the cells to the normally non-toxic antiviral drug, ganciclovir (GCV). 1 The antitumor activity is the result of HSVtkexpressing tumor cells activating GCV to its cytotoxic triphosphate derivative which competes with endogenous dGTP for incorporation into DNA interfering with cellular DNA synthesis. 2, 3 HSVtk/GCV cancer gene therapy has been successful in vitro with a number of tumor cell lines and has produced complete tumor regressions in animal models, [4] [5] [6] [7] [8] [9] [10] which has been the impetus for the development of clinical trials for the treatment of brain and ovarian tumors. 11 This form of therapy not only benefits from, but is also dependent on a phenomenon know as the 'bystander effect', whereby a small percentage of HSVtk-expressing cells causes GCV-mediated cell death to tumor cells which are not expressing the transgene. 1, 12, 13 GCV elicits a multi-log cell kill in HSVtk-expressing cells in a wide variety of tumor cell lines, including human glioblastoma and colon carcinoma cell lines. 14, 15 Functional gap junctional intracellular communication (GJIC) increased bystander cytotoxicity. [16] [17] [18] [19] [20] [21] We have previously quantitated the transfer of phosphorylated GCV from HSVtk-expressing cells to bystander cells (bystander effect) over time in both U251 glioblastoma and SW620 colon carcinoma cell lines. 14, 22 With human U251 glioblastoma cells, which exhibit a high level of GJIC, transfer of phosphorylated GCV was observed as early as 4 h after drug addition. 23 Although GJIC was nearly absent in SW620 cells, transfer of phosphorylated GCV and bystander killing was also observed and was dependent on the level of HSVtk expression, the number of cells expressing HSVtk and the overall confluency of the cells.
14 However, the level of GCV nucleotide transfer to bystander cells was two-fold greater in U251 cells compared with SW620 cells resulting in a five-fold increase in bystander cell cytotoxicity between cell lines. 14, 22 Poor tumor responses have been reported in clinical trials utilizing HSVtk/GCV cancer gene therapy. 23 These failures may have been the result of inadequate expression of the HSVtk gene. Current methodologies for transducing genes in vivo usually allow only a small proportion (р10%) of a tumor to actually express the transgene. 11 Bystander killing is critical for clinical success and eradication of tumors and enhancing the efficiency of bystander killing may offer new strategies for improving the clinical application of HSVtk/GCV gene therapy. In a more recent publication, we demonstrated that decreasing GCV's endogenous competitor, dGTP, synergistically enhanced GCV-mediated bystander cytotoxicity in several cell lines in vitro. 24 In SW620 bystander cells, addition of the ribonucleotide reductase inhibitor, hydroxyurea (HU), reduced the level of endogenous dGTP and increased the accumulation of GCV triphosphate to levels similar to those detected in HSVtk-expressing cells in the absence of HU. Following drug removal, GCV monophosphate incorporation into DNA was also elevated when HU was present. In addition, synergy was observed even when less than 10% of the co-culture was expressing HSVtk, where the addition of HU significantly reduced the IC50 of GCV to more clinically relevant doses. 24 To determine if HU would improve the efficacy of the HSVtk/GCV gene therapy strategy in vivo, we extended these experiments using a murine xenograft tumor model. In this study, GCV treatment alone had little effect on tumors consisting of 1:1 and 1:10 mixtures of HSVtk-and LacZ-expressing SW620 cells. However, GCV in combination with HU was effective in delaying tumor growth and resulted in a single complete tumor regression from each group.
Results

Effect of HU and GCV on DNA synthesis inhibition and cell cycle distribution
We have previously demonstrated that addition of 2 mM HU to SW620 colon carcinoma cells in culture resulted in 50-75% cell death as determined by clonogenic survival. 24 At this concentration, both a decrease in cellular dATP and dGTP levels and an inhibition of DNA synthesis were observed. 24 In combination with GCV, 2 mM HU increased the ratio of GCV-TP:dGTP up to seven-fold in HSVtk-expressing cells and lowered the sensitivity of bystander cells to GCV. To better characterize the DNA synthesis inhibition caused by HU treatment and its contribution to the synergy associated with GCV cytotoxicity, we performed dual parameter flow cytometry on SW620 cells stably expressing HSVtk. In Figure 1 , DNA content was measured with propidium iodide and the level of DNA synthesis was determined by 5-bromo-2'-deoxyuridine (BrdUrd) incorporation. The addition of 2 mM HU almost completely eliminated DNA synthesis at 4 h as demonstrated by the dramatic decrease in FITC fluorescence ( Figure 1, second panel) . Following 12 and 24 h of HU treatment, BrdUrd incorporation into DNA was inhibited by 93% and 87%, respectively, compared with untreated control (0 h) cells. The 24-h incubation with 2 mM HU resulted in a 32% decrease in cell growth. Following HU removal, DNA synthesis recovered to con- trol levels, and cells began to grow after 24 h and normal cell cycle progression was observed over the next 72 h (data not shown). Figure 2 illustrates the ability of SW620 co-cultures containing an equal number of HSVtk-expressing and LacZ-expressing (bystander) cells to progress through the cell cycle after treatment with either 10 M GCV alone or in combination with 2 mM HU. Compared with untreated control cells, DNA synthesis (BrdUrd incorporation) was inhibited 75% with GCV alone and 97% with both GCV and HU following a 24-h drug exposure (Figure 2 0 h ). DNA synthesis increased approximately to control levels in both GCV and GCV/HU treated co-cultures over the next 24 h in the absence of drugs. During this time period, DNA synthesis increased two-fold in GCV-treated cells and 15-fold in GCV/HU-treated cells. However, during subsequent time-points, GCV/HU-treated cells progressed through the cell cycle very slowly compared with GCV treatment alone. Forty-eight hours after drug washout, the G 1 population nearly doubled in GCV-treated cells (compared with a Ͻ20% increase in GCV/HU-treated cells) indicating the S phase cells were progressing through the cell cycle. During the same period, GCV/HU-treated cells remained primarily (64%) in late S phase. The cell cycle pattern in GCV/HU-treated co-cultures continued to remain unchanged у72 h after drug washout and the number of cells decreased steadily over this time (7.50 × 10 6 cells at 0 h to 2.71 × 10 6 cells at 96 h). In contrast, the GCV-treated cells appeared to progress through the cell cycle while the number of cells remained constant suggesting that a population of this co-culture was growing.
In vitro GCV cytotoxicity with HU and aphidicolin
Since HU appears to synchronize cells in S phase following drug washout, we decided to measure the clonogenic survival of LacZ-expressing bystander cells following concurrent addition or pre-incubation of another drug which is also capable of S phase synchronization to determine if we could reproduce the increase in GCV cytotoxicity observed with HU. 1:1 co-cultures of HSVtk and LacZ-expressing cells where treated with two doses of GCV (1.0 and 10 M) in the presence or absence of 2 mM HU or 1 M aphidicolin. Aphidicolin is an inhibitor of replicative DNA polymerases and inhibits DNA synthesis without a corresponding decrease in deoxynucleotides. 25 At these concentrations, growth inhibition and DNA synthesis inhibition are similar to HU. When incubated with both aphidicolin and GCV for 24 h, bystander cells were actually protected from the cytotoxic effect of GCV. Twice as many bystander cells survived 10 M GCV treatment when 1 M aphidicolin was added (Table  1 ). In addition, the amount of GCV monophosphate incorporation into bystander cell DNA was two-to threefold higher in HU-treated co-cultures compared with aphidicolin treatment (data not shown).
Figure 2 Effects of GCV and HU on the cell cycle distribution of SW620 co-cultures containing an equal number of HSVtk and LacZ-expressing cells. Cells were incubated with either 10 M GCV or the combination of 10 M GCV and 2 mM HU for 24 h. Control represents a 24-h period without addition of either GCV or HU. Drug containing medium was removed following the 24-h incubation (indicated at time = 0 h) and replaced with fresh drug-free medium. Cells were analyzed every 24 h after drug removal over a 96-h period with fresh medium supplied every 24 h. Cells were incubated
Since a substantial block in DNA synthesis was initially Gene Therapy observed after a 4-h incubation with HU ( Figure 1 ), we decided to examine the effects of a shorter incubation or pre-incubation with HU. A 4-h pretreatment with HU exhibited similar bystander cytotoxicity as both drugs given together. In addition, a 4-h HU incubation followed by 24 h with GCV alone demonstrated that 4 h was sufficient for an increased cytotoxicity (Table 1) . However, a 24-h HU pretreatment followed by 24-h incubation with both HU and GCV resulted in decreased bystander killing, 44 ± 2.9% with 1 M GCV and 16 ± 2.3% 10 M. If cells were pretreated with GCV before addition of HU, bystander killing was higher compared with GCV alone, but was decreased compared with concurrent addition of the drugs. A 4-h pre-incubation with aphidicolin did not increase cytotoxicity with 10 M GCV ( Table 1) .
Sensitivity of SW620 tumors to GCV and HU in a murine xenograft model
To investigate whether the synergy observed in our in vitro assays 24 would correspond to increased GCV cytotoxicity in vivo, we used a mouse xenograft model with SW620 mixtures containing 100%, 50% and 10% HSVtkexpressing cells. Between 8-10 × 10 6 cells were injected s.c. and drug treatment was initiated when tumors reached~150 mm 3 . HU is rapidly eliminated from both humans (t 1/2~4 h) and nude mice (t 1/2~1 1 min). [26] [27] [28] Mayhew et al 29 treated mice with 500 mg/kg/day HU for 10 weeks without signs of gross toxicity or significant differences in body weight, although hematopoietic toxicity occurred past 2 weeks. In preliminary studies, we treated nude mice for 5 consecutive days with 500, 1000 or 1500 mg/kg HU without any observed adverse behavior effects or weight loss during treatment or 100 days following treatment (data not shown). From the above results, we decided to treat animals concurrently with GCV and with a high concentration of HU on a daily basis to achieve inhibition of ribonucleotide reductase in tumor cells. Mice received i.p. PBS (control), GCV alone (100 mg/kg), HU alone (1500 mg/kg) or a combination of 100 mg/kg GCV and 1500 mg/kg HU once daily over 5 consecutive days. Mice were monitored daily and weighed every other day. Animals receiving both drugs in combination experienced weight loss (4-13%) beginning approximately 4 days into the drug treatment. Weight returned to normal in these animals within a week following the end of the 5-day drug period. In Figure 3 , tumor growth was measured over time in mice that received a 1:1 mixture of HSVtk and LacZ-expressing cells and treated with GCV alone or in combination with HU. During drug treatment, tumors in mice receiving both GCV and HU showed greater delays in growth compared with GCV treatment alone, with many of the tumors actually decreasing below their initial size. At the end of the 5-day drug period, GCV/HU-treated mice had a median tumor size of 226 ± 16 mm 3 compared with 567 ± 42 mm 3 (P Ͻ 0.0001) for GCV-treated mice. Animals treated with the combination of GCV and HU also had a significant reduction in tumor growth over the course of the experiment compared with GCV treatment alone. The median tumor size was 596 ± 89 mm 3 compared with 1116 ± 102 mm 3 (P Ͻ 0.0033) on day 20 and 1484 ± 322 mm 3 versus 2574 ± 215 mm 3 (P Ͻ 0.0183) on day 29. One tumor in the GCV/HU group increased in size to~800 mm 3 on day 30 then decreased in size over the next 45 days and was undetectable up to day 100 when the animal was killed. Similar results were seen in animals with tumors consisting of 10% HSVtk-expressing cells including a complete tumor regression in an animal treated with both drugs. These results are summarized in Figure  4 as the amount of time necessary for tumors to reach approximately 10 times their initial size. When 100% HSVtk-expressing cells were implanted, GCV and the combination of GCV and HU were similar in their effects on tumor growth and resulted in two tumor regressions in each group. The median number of days to reach a tumor size of 1500 mm 3 was significantly higher in animals treated with GCV and HU compared with animals treated with GCV alone in tumors consisting of 10% (P Ͻ 0.05) or 50% (P Ͻ 0.02) HSVtk-expressing cells. In experiments where mixtures of HSVtk and LacZ-expressing co-cultures were injected into animals, survival was similar between control and GCV treatment alone ( Figure  5 ). Survival is improved with the combination of GCV and HU in all samples compared with control or single drug treatment. Only with 100% HSVtk-expressing tumors did this dose of GCV have an effect on tumor Figure 3 . Animals were killed when tumors exceeded a size between 2500 and 3000 mm 3 
Figure 4 Effect of GCV and HU on established s.c. tumors implanted as 1:10 or 1:1 co-cultures of HSVtk and LacZ-expressing SW620 cells or as 100% HSVtk-expressing SW620 cells. Animals were treated with i.p. injections once daily over 5 days with PBS (control), 1500 mg/kg HU, 100 mg/kg GCV alone or a combination 100 mg/kg GCV and 1500 mg/kg HU. The horizontal bar represents the mean number of days for the tumors in each
Figure 5 Kaplan-Meier survival analysis of the s.c. SW620 tumors treated with PBS () HU alone (̆), GCV alone (᭜) or the combination of GCV and HU (᭹) presented in
or after 100 days if tumors were not measurable. Data are from groups of six animals with tumors containing 10% (left panel), 50% (middle panel) and 100% (right panel) HSVtkexpressing cells.
growth (P Ͻ 0.02 compared with control) and animal survival. Although the addition of HU produced a longer delay in tumor growth, the difference was not significantly different compared with treatment with GCV alone (P Ͻ 0.22).
Discussion
We have previously evaluated both the mechanism of GCV cytotoxicity 16 and the ability of HU to enhance GCV-mediated bystander killing in an in vitro HSVtk/GCV enzyme-prodrug model. 24 In U251 human glioblastoma cells that stably express HSVtk, a 24-h treatment with GCV at doses which produced a 4 to 5 log cell kill did not result in a strong inhibition of DNA synthesis.
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Cells proceeded through S and G 2 /M phases during and following exposure to drug, doubling in cell number 48 h after drug washout. During the second cell cycle, GCVtreated cells accumulated in early S phase and remained there until cell death, suggesting that cytotoxicity was dependent on incorporation of GCV-MP into the DNA template. 16 This can also be observed with GCV-treated SW620 cells in Figure 2 , where cells were able to progress through the cell cycle 48 h following drug washout. We have previously reported that following a 24-h incubation with 2 mM HU, GCV-MP incorporation was decreased 60% in HSVtk-expressing cells, 24 consistent with the strong DNA synthesis inhibition observed in Figures 1 and 2 . However, from 4 to 12 h following drug removal, GCV-MP is rapidly incorporated into DNA, and after 24 h there is an accumulation of cells in early S phase (Figure 2) . In contrast to the cells treated with GCV alone, these cells progress slowly through S phase over a number of days and appeared to die without going through cell division, arresting in late S phase. The number of GCV/HU-treated cells declined steadily over time and 72 h after drug removal had decreased over 50% from the time of drug addition. These results may suggest that a different mechanism of cytotoxicity may be utilized when HU is present and GCV may not be required to be present in the DNA template. One possibility that would warrant additional investigation is the ability of HU to alter DNA repair by disrupting endogenous dNTP levels and simultaneously increasing the number of damaged sites by increasing GCV-MP in the DNA. HU has been proposed to inhibit repair of DNA lesions and delay the resynthesis at damaged sites, 30 while imbalances in dNTP pools have been shown to activate cellular endonuclease resulting in apoptosis. 31, 32 Hydroxyurea produces a potent block in DNA synthesis (95% inhibition) as soon as 4 h after addition (Figure 1) . By 24 h a significant number of cells were synthesizing DNA (Figure 1 ) and 24 h following exogenous drug removal the majority of the cell population had resumed DNA synthesis as measured by BrdUrd incorporation ( Figure 2 ). To test whether this DNA synthesis inhibition and cell cycle synchronization contributed to enhanced GCV-mediated cytotoxicity we treated SW620 co-cultures with GCV and aphidicolin. Aphidicolin is an inhibitor of replicative DNA polymerases that does not significantly interfere with protein, RNA or nucleotide synthesis and has been previously used to synchronize cells in culture. 25, 33, 34 DNA synthesis inhibition, cell cycle distribution and growth inhibition was similar between HU and aphidicolin (data not shown). However, concurrent addition of GCV and aphidicolin actually protected both HSVtk-expressing and bystander cells from the cytotoxic effects of GCV (Table 1) . Similar to HU, aphidicolin significantly decreased GCV-MP incorporation into DNA during a 24-h drug incubation, but unlike HU treatment, aphidicolin decreased the amount of GCV triphosphate accumulation by as much as 50%. 35 These data suggest that the increased sensitivity to GCV with HU is not merely due to the inhibition of DNA synthesis, but more likely due to perturbations in dNTP pools and a higher GCV-TP:dGTP ratio favoring incorporation of GCV-MP into DNA. In fact, preliminary experiments using GCV and 2',2'-difluoro-2'-deoxycytidine (dFdCyd, gemcitabine), which inhibits ribonucleotide reductase by a different mechanism, also synergistically enhances GCV-mediated bystander killing. dFdCyd produced a dose-dependent decrease in cellular dGTP levels (approximately 4% of control at 50 M). No significant increase was observed in GCV-TP accumulation, however, with the substantial decrease in endogenous dGTP the GCV-TP:dGTP ratio was increased over 10-fold. 36 We are currently investigating a number of other proposed dNTP synthesis inhibitors.
In our animal experiments, we demonstrated that with tumors consisting entirely of HSVtk-expressing cells, an equal number of tumor regressions were observed and survival was similar between animals receiving a combination of HU and GCV and GCV treatment alone (Figures 4 and 5) . However, a tumor expressing this high level of HSVtk is not a clinically relevant model. The ability to enhance GCV-mediated bystander killing in vivo in this therapeutic approach is important given the poor responses observed so far in clinical trials due to the low efficiencies of gene transfer currently obtainable in gene transfer. 12 This is especially evident in tumor growth and survival curves in animals injected with 10% and 50% HSVtk-expressing cells, where treatment with GCV alone produced results that were not significantly different to PBS treatment. Colon carcinoma cell lines have also been shown to be less sensitive to GCV than other cell lines, such as glioblastomas. 15, 16 In addition, the level of gap junctional intercellular communication in SW620 cells is poor with cells that are capable of transferring dye to only 3% of neighboring cells. 15 However, this low level of GJIC may be more analogous to clinical tumors which exhibit little to no GJIC. 37 In spite of these apparent hurdles, HU was able to render SW620 tumors expressing mixtures of HSVtk-and non-expressing cells more sensitive to GCV, delaying tumor growth and even resulting in complete tumor regression (Figures 3 and 4) .
In this study, we have demonstrated a pharmacological means of improving the efficacy of HSVtk/GCV gene therapy in vivo. HU already has a proven history of clinical application and has been shown to be a good biochemical modulator in combination with other chemotherapeutic agents. 26 In addition, HU treatment could be used with a variety of expression vectors, tissue specific vectors, or more active HSVtk mutants. This strategy also has the advantage of not requiring additional transgene expression such as previously reported connexin overexpression 38, 39 or addition of a second suicide gene. [40] [41] [42] These data suggest that HU may be a potential candidate for clinical testing and further in vivo characterization including drug scheduling and toxicity are warranted.
Materials and methods
Cell culture and generation of stable cell lines
The SW620 human colon carcinoma cell was cultured in McCoys 5A medium supplemented with 2 mM L-glutamine and 10% fetal bovine serum (Gibco BRL, Grand Island, NY, USA). Cells were maintained in exponential growth in a humidified incubator at 37°C in an atmosphere of 5% CO2 and 95% air. SW620 clonal cell lines which stably express HSVtk or ␤-galactosidase were developed from their parental cell line using a retrovirus vector containing the corresponding cDNA controlled by the 5' long terminal repeat sequence and have been previously characterized. 15 Cell cycle progression and DNA synthesis Flow cytometric analysis was performed as previously described. 43 Briefly, at the conclusion of the drug incubation, cells were pulse labeled with 30 M BrdUrd for 15 min, and then harvested by trypsinization, counted, and fixed in cold 70% ethanol. Fixed cells were resuspended in 0.5 mg/ml RNAse A (Boehringer Mannheim, Indianapolis, IN, USA) and incubated for 30 min at 37°C. Cells were then subjected to 0.1 N HCl containing 0.7% Triton X-100 (10 min on ice), followed by a 95°C incubation for 15 min in sterile water. One hundred l of PBS containing 0.5% Tween 20 and 5% calf serum (PBT) was added to each cell pellet followed by the addition of 100 l of anti-BrdUrd mouse IgG1 antibody (1:100 dilution; PharMingen, San Diego, CA, USA) and incubation for 30 min at room temperature. After centrifugation, 150 l of FITC conjugated goat anti-mouse IgG antibody (1:20-35 dilution; Sigma Chemical, St Louis, MO, USA) was added to the pellet, mixed gently, and incubated for 30 min at room temperature. Samples were centrifuged and resuspended in 0.5 ml of 18 g/ml propidium iodide containing 40 g/ml RNAse A. Trout erythrocyte nuclei (Biosure, Grass Valley, CA, USA) were added as an internal standard. Treated cells were placed in the dark for a minimum of 30 min before cell cycle analysis using a Coulter EPICS Elite ESP flow cytometer (Coulter, Hialeah, FL, USA). Cell cycle data were further analyzed using WinMDI software (ver 2. 
Clonogenic survival assays
Cytotoxicity was measured in SW620 co-cultures that contained an equal number HSVtk-and LacZ-expressing cells and treated with 0.01 to 10 M ganciclovir (Cytovene, Syntex, Palo Alto, CA, USA) and/or 2 mM HU (Sigma Chemical) or 1 M aphidicolin (Sigma Chemical) for 24 h. In some experiments, co-cultures were pretreated with GCV, HU or aphidicolin for 4 h, followed by removal of drug containing media and replacement of fresh growth medium containing the appropriate drug. After the 24 h drug treatment, cells were trypsinized, counted with a Coulter electronic particle counter and diluted to approximately 100 viable cells per 35-mm diameter well in six-well culture dishes. After 10 days, the resulting cell colonies were fixed in 1% (v/v) glutaraldehyde, and bystander cell survival was measured by staining with 0.2% 5-bromo-4-chloro-3-indolyl-B-D-galactoside (X-gal, Boehringer Mannheim). Cell survival was expressed as a fraction of plating efficiency for untreated cells. All colony formation assays were performed independently at least twice and each point was plated in triplicate.
In vivo analysis
Female athymic (nu/nu) nude mice (Charles River, Kingston, NY, USA), 6-8 weeks of age were used for a xenograft model. All experimental procedures and animal care conforms to the standards in The Guide for the Care and Use of Laboratory Animals (NIH 85-23, revised 1985). Eight to 10 million cells in 200 l saline were injected s.c. into the left flank of the animal. Implanted cells consisted of 100% SW620 HSVtk-expressing cells or co-cultures of 1:1 or 1:10 HSVtk and LacZ-expressing cells. Tumors were allowed to grow to approximately 150 mm 3 , usually 5-7 days, at which time drug treatment began. GCV (100 mg/kg), HU (1500 mg/kg) or a combination of both drugs was administered i.p. in approximately 1 ml saline once daily for 5 consecutive days. Bidirectional tumor measurements were recorded approximately every other day with calipers and tumor volume was reported as l × w 2 . 44, 45 Animals were killed with CO 2 when tumor volume exceeded 2500-3000 mm
